Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 8/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21310995 | 0.89 | GAA (0.57) | LNPEPERAP2KDM4EALDH1A1GAA | |
| SCHEMBL24959076 | 0.87 | HDAC1 (0.49) | LNPEPHDAC1ERAP2KDM4EALDH1A1 | |
| SCHEMBL23286806 | 0.85 | HDAC1 (0.47) | LNPEPHDAC1ERAP2KDM4EALDH1A1 | |
| SCHEMBL6351226 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL23286815 | 0.84 | HDAC1 (0.46) | LNPEPHDAC1ERAP2KDM4EALDH1A1 | |
| SCHEMBL23286924 | 0.84 | LNPEP (0.48) | LNPEPHDAC1ERAP2KDM4EALDH1A1 | |
| SCHEMBL2014323 | 0.82 | LNPEP (0.56) | LNPEPHDAC1ERAP2KDM4EALDH1A1 | |
| SCHEMBL23286896 | 0.82 | HDAC1 (0.44) | LNPEPHDAC1ERAP2KDM4EALDH1A1 | |
| SCHEMBL24265280 | 0.81 | HDAC1 (0.53) | LNPEPHDAC1ERAP2KDM4EALDH1A1 | |
| SCHEMBL23273578 | 0.80 | PTGER4 (0.49) | LNPEPHDAC1ERAP2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2023070114-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023070114-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| WO-2019162323-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| EP-2410857-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111058-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | LNPEP 3213/4885HDAC1 1025/4885ERAP2 2726/4885 |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | LNPEP 2453/4885HDAC1 3458/4885ERAP2 890/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | LNPEP 2924/4885HDAC1 995/4885ERAP2 3088/4885 |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | EGFR, ERBB2, ERBB3 | LNPEP 156/4885HDAC1 889/4885ERAP2 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.